Semax Peptide

Semax is a synthetic linear heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its one-letter sequence, MEHFPGP, records seven residues in a defined order. The substance is described as an ACTH(4-10) analogue because the seven-residue designation relates it to that segment of adrenocorticotropic hormone. A second structural description, ACTH(4-7) followed by Pro-Gly-Pro, specifies how the reference sequence is assembled.

The identifiers below refer to the free peptide represented in the database record. They provide reconciliation points for a reference structure, but none alone authenticates supplied material. Sequence, formula and mass must be interpreted alongside the documented chemical form.

These values describe a database reference structure, not the commercial batch. A matching designation is only one part of material reconciliation, and batch identity remains a separate analytical question.

Chemical context: PubMed index

BDNF and TrkB name a pathway-focused research area, not a settled account of Semax. The cited preclinical rat models measured several different variables: BDNF protein abundance, BDNF exon III transcript abundance, trkB transcript abundance, TrkB tyrosine phosphorylation and specific binding. A measurement at one layer does not establish a change at another layer, and simultaneous observations do not establish a universal causal chain.

The two 2006 records also concern different anatomical contexts: one reports hippocampal measurements in a preclinical rat model, while the other reports basal-forebrain measurements in a preclinical rat model. Tissue, assay, sampling time and comparator remain part of each observation. The records therefore do not justify the simplified statement that Semax uniformly “raises BDNF”. Nor do these molecular measurements establish properties of a supplied batch.

Pathway-context records: PubMed index

This section describes findings in controlled research and makes no statement about use. All six sources are preclinical rodent studies; this evidence map contains no in-vitro, human or review layer. The rows are ordered by measurement layer, from binding and protein through neurochemistry, transcriptomics and proteomics to biochemical parameters. That order is organisational, not an evidential hierarchy.

Model names describe experimental systems, not indications. Across the six records, anatomical setting, analytical platform, comparator and sampling schedule differ. Binding, protein, phosphorylation, transcript, monoamine, proteomic, nitric-oxide and lipid-peroxidation measurements must therefore remain separate. The cited source set also provides no single transferable half-life value; stability depends on matrix, method and conditions.

Study sources: PubMed evidence index

“ACTH(4-10) analogue” and “ACTH(4-7) followed by Pro-Gly-Pro” are complementary descriptions of Semax nomenclature. The former places the seven-residue sequence in relation to an ACTH segment; the latter spells out the N-terminal relationship and C-terminal PGP extension. Neither phrase changes the reference sequence MEHFPGP.

N-acetyl Semax amidate is chemically modified and is not a synonym for the free peptide documented here. It is a separate research material, so its name, chemical form, identifiers and analytical records must not be substituted for those of Semax.

Semax and Selank are distinct research peptides. Semax is ACTH-derived and has the sequence MEHFPGP; Selank is tuftsin-derived and has the sequence TKPRPGP. Their shared C-terminal PGP motif does not make them equivalent, and findings are not transferable between them. Each requires its own identity data, model-specific literature and batch documentation. This distinction is neither a ranking nor a recommendation.

Reborn Peptides frames Semax strictly as a research peptide. The research record is organised by named substances, defined rodent models and discrete analytical endpoints.

Terminology context: PubMed index

Laboratory procurement should reconcile the designation, sequence, reference identifiers and batch code with the released product specification and the matching batch documentation. The applicable COA should connect the test date, analytical method and reported finding to the same batch. Literature records establish neither the identity nor the analytical characteristics of supplied material.

Any purity statement must be batch- and method-specific. HPLC can document a chromatographic profile or a method-specific purity finding for the tested batch, but it does not automatically establish molecular identity. MS interpretation depends on the documented form, counter-ions, adducts and acceptance criteria. The label, released specification, MS record and applicable COA must be reconciled before an identity or purity statement is made.

No storage condition, temperature, stability period or shelf-life statement is made here. Research supply documentation and preclinical literature serve different purposes and cannot substitute for one another. The material is strictly for laboratory research, not for use in humans or animals.

Research use only. For laboratory research only. Not for human or veterinary use. Not intended to diagnose, treat, cure or prevent any disease. Not a medicinal product, food or cosmetic.